Related Experiment Video
Updated: Jul 5, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Costs of payment in Thai acute coronary syndrome patients
Worachat Moleerergpoom1, Rungsrit Kanjanavanit, Woravut Jintapakorn
1Cardiology Unit, Department of Medicine, Police General Hospital, Pratumwan, Bangkok 10330, Thailand. drworachat@hotmail.com
Insights
The cost of acute coronary syndrome (ACS) treatment in Thailand varies significantly based on diagnosis, hospital type, and patient payment method. Key factors like percutaneous coronary intervention (PCI) and length of stay independently predict higher healthcare expenditures.
Area of Science:
- Cardiology
- Health Economics
- Public Health
Background:
- Acute coronary syndrome (ACS) poses a significant financial burden on patients globally, including in Thailand.
- Estimating the direct treatment costs for ACS patients is crucial for understanding the economic impact.
- Hospital charges from ACS registry data offer an approximation of patient expenditures during initial admission.
Purpose of the Study:
- To calculate the patient costs associated with ACS, considering diagnostics, demographics, treatments, payer types, hospital profiles, and outcomes.
- To identify independent predictors for treatment costs in ACS patients using appropriate statistical models.
Main Methods:
- Analysis of data from the second and third phases of the Thai ACS registry (TACSR).
- Inclusion of 3,552 patients diagnosed with new-onset ACS.
- Utilizing multiple linear regression models to identify cost predictors.
Main Results:
- Median patient cost was 47,908 baht, with significant variations based on ACS type (STEMI, NSTEMI, UA).
- Costs were higher in private hospitals compared to government hospitals and varied by payer type.
- Treatments like primary PCI and invasive strategies in NSTEMI/UA were associated with higher costs; length of stay and complications were key predictors.
Conclusions:
- Treatment costs for ACS patients in Thailand exhibit considerable variation across diagnostic groups.
- Hospital type, payer, referral system, treatment procedures, medications, and complications are significant factors influencing costs.
- Several clinical factors independently predict the overall cost of ACS management.
Background:
Acute coronary syndrome (ACS) is a major health care syndrome that can financially burden patients throughout the world, including Thailand. Few studies purposed estimating the costs of treatment. The data from the ACS registry database represented the costs of hospital charges paid by ACS patients. Although these were not the actual treatment costs, the authors can approximately estimate the total expenditure for the first admission.
Objectives:
First, calculate the cost of ACS to the patients, including diagnostic, demographic data, treatment modalities, type of payers, hospital profile, and outcomes. Second, find the appropriate model to identify the independent factors for predicting the treatment costs.
Material And Method:
The present study collected data from the second and third phase of a national multicenter prospective registry of ACS in Thailand, Thai ACS registry (TACSR). 3,552 patients with new onset of ACS were analyzed.
Results:
Median age was 67 years (range 26.5-105.5) with predominately male and median length of stay (LOS) was 7 days (range, 1-184). 42% referred from other hospitals. The median cost of the total population was 47,908 baht (range, 633-1,279,679). When classified into those of STEMI, NSTEMI, and UA, the costs were 82,848.5, 40,531 and 26,116 baht respectively, p < 0.0001. Patients in the government hospital had to pay the total cost with PCI and CABG, 152,081-161,374 baht and 203,139-223,747 baht respectively, while the private hospital charged almost twice as much. For the types of payers, private insurance including private employee security fund paid significantly more than others. Costs in patients paid by "30 baht na tional health scheme and social security fund" were significantly less than those of others. For modality of treatment in STEMI, primary PCI was significantly more costly than thrombolytics and no reperfusion therapy, 161,096.5 vs. 60,043.0 and 33,335.0 baht respectively p < 0.0001. Early invasive groups in NSTEMI/UA had much higher median costs 145,794.0 baht when compared to those of the conservative group, 47,908 baht, p < 0.0001. Two multiple linear regression models according to the diagnostic group identified the independent factors for predicting cost. PCI, LOS, CABG, admission in a private hospital, Death, GPIIb/IlIa inhibitors use, major bleeding, coronary angiogram, thrombolytics use, age and diabetes were independent predictors for the cost in STEMI patients, R2 = 0.58. For those of NSTEMI/UA, the independent predictors for the cost were PCI, LOS, CABG, admission in a private hospital, death, GP IIb/IIIa inhibitors use, major bleeding, coronary angiogram, age, ventricular arrhythmia, CHF and referred patients, R2 =0.62.
Conclusion:
Costs in ACS patients were markedly different among diagnostic groups. The clinical risk factors were hospital type, type of payers, referred system, treatment procedures, drugs used and complications including outcome. Some of these factors could independently predict the costs.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations